Paper786362
5-year follow-up of cytotoxic chemotherapy as an adjuvant to surgery in carcinoma of the bronchus.
Stott H and 3 others. Br J Cancer, 1976. Cited by 27 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. 5-year follow-up of cytotoxic chemotherapy as an adjuvant to surgery in carcinoma of the bronchus. Papers, record 786362. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/786362
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- 5-year follow-up of cytotoxic chemotherapy as an adjuvant to surgery in carcinoma of the bronchus.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bronchial Neoplasms | Major topic |
| Busulfan | Major topic |
| Cyclophosphamide | Major topic |
| Clinical Trials as Topic | |
| Female | |
| Follow-Up Studies | |
| Humans | |
| Male | |
| Neoplasm Metastasis | |
| Prognosis | |
| Thrombocytopenia |
Source PubMed
References16
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 14260622 | SURGICAL TREATMENT OF CARCINOMA OF THE BRONCHUS. | Br Med J | 1965 | https://conductscience.org/library/papers/14260622 | PubMed |
| 2 | 4164768 | Survival in 6086 cases of bronchial carcinoma. | Lancet | 1967 | https://conductscience.org/library/papers/4164768 | PubMed |
| 3 | 4188368 | Combined surgery and chemotherapy for carcinoma of bronchus. | Lancet | 1970 | https://conductscience.org/library/papers/4188368 | PubMed |
| 4 | 4336754 | Lung cancer: perspectives and prospects. | Ann Intern Med | 1970 | https://conductscience.org/library/papers/4336754 | PubMed |
| 5 | 4343295 | Use of chemotherapy as an adjuvant to surgery for bronchogenic carcinoma. | Cancer | 1972 | https://conductscience.org/library/papers/4343295 | PubMed |
| 6 | 4322068 | An assessment of massive-dose chemotherapy of malignant disease. | Can Med Assoc J | 1971 | https://conductscience.org/library/papers/4322068 | PubMed |
| 7 | 4199643 | Effects of long-term adjuvant chemotherapy with cyclophosphamide (NSC-26271) for radically resected bronchogenic carcinoma. | Cancer Chemother Rep 3 | 1973 | https://conductscience.org/library/papers/4199643 | PubMed |
| 8 | 53654 | Treatment of inoperable carcinoma of bronchus. | Lancet | 1975 | https://conductscience.org/library/papers/53654 | PubMed |
| 9 | 4729324 | Chemotherapeutic studies in bronchogenic carcinoma by the Austrian study group. | Cancer Chemother Rep 3 | 1973 | https://conductscience.org/library/papers/4729324 | PubMed |
| 10 | 4729321 | Remission rates, survival, and prognostic factors in combination chemotherapy for bronchogenic carcinoma. | Cancer Chemother Rep 3 | 1973 | https://conductscience.org/library/papers/4729321 | PubMed |
| 11 | 5030808 | Importance of dose schedules in adjuvant chemotherapy. | Cancer Chemother Rep | 1972 | https://conductscience.org/library/papers/5030808 | PubMed |
| 12 | 5284190 | Survival in lung cancer; effectiveness of surgery. | N Y State J Med | 1971 | https://conductscience.org/library/papers/5284190 | PubMed |
| 13 | 781905 | An investigation of the chest radiographs in a controlled trial of busulphan, cyclophosphamide, and a placebo after resection for carcinoma of the lung. | Thorax | 1976 | https://conductscience.org/library/papers/781905 | PubMed |
| 14 | 5791000 | Alkylating agents in bronchogenic carcinoma. | Am J Med | 1969 | https://conductscience.org/library/papers/5791000 | PubMed |
| 15 | 5779756 | Prognostic factors in lung cancer. Surgical aspects. | Ann Thorac Surg | 1969 | https://conductscience.org/library/papers/5779756 | PubMed |
| 16 | 6021150 | Bronchogenic carcinoma. Factors in survival. | Arch Surg | 1967 | https://conductscience.org/library/papers/6021150 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 27 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 23940101 | The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: a report from the Childhood Cancer Survivor Study. | Pediatr Blood Cancer | 2014 | https://conductscience.org/library/papers/23940101 | PubMed |
| 17369673 | As depressing as it was predictable? Lung cancer, clinical trials, and the Medical Research Council in postwar Britain. | Bull Hist Med | 2007 | https://conductscience.org/library/papers/17369673 | PubMed |
| 7028069 | Failure of specific active immunotherapy in lung cancer. | Br J Cancer | 1981 | https://conductscience.org/library/papers/7028069 | PubMed |
| 3907687 | Fifteen-year follow-up of all patients in a study of post-operative chemotherapy for bronchial carcinoma. | Br J Cancer | 1985 | https://conductscience.org/library/papers/3907687 | PubMed |
| 832067 | Adjuvant therapy of lung cancer: now sits expectation in the air. | Br Med J | 1977 | https://conductscience.org/library/papers/832067 | PubMed |
| 589308 | Acute leukaemia after busulphan. | Br Med J | 1977 | https://conductscience.org/library/papers/589308 | PubMed |
| 358479 | Adjuvant immunotherapy with BCG in squamous-cell bronchial carcinoma. Immune-reactivity in relation to immunostimulation (preliminary results in a controlled trial). | Thorax | 1978 | https://conductscience.org/library/papers/358479 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/786362
GET https://conductscience.org/api/papers/v1/786362/authors